AnalystsArthur HeArthur He's Stock Forecasts
AnalystsArthur He
Sectors:
Industries:
Analyst Ranking
Top 4%
#162 out of 5136 analysts
Average Return
+43.91%
Win Rate
59%48 out of 81
Risk vs Reward
Poor
Good
Arthur He's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Nektar TherapeuticsNKTR | +368.32% | $12.23 | $57.28 | 2025-03-13 - 2025-12-08 | Buy |
Nektar TherapeuticsNKTR | +338.69% | $13.06 | $57.28 | 2025-02-25 - 2025-12-08 | Buy |
Poseida Therapeutics IncPSTX | +335.27% | $2.16 | $9.38 | 2024-04-22 - 2024-11-26 | Buy |
Nektar TherapeuticsNKTR | +297.25% | $14.42 | $57.28 | 2025-01-13 - 2025-12-08 | Buy |
Poseida Therapeutics IncPSTX | +294.12% | $2.38 | $9.38 | 2024-10-30 - 2024-11-26 | Buy |
Arthur He Analyst Color
Get additional color on Arthur He's coverage of popular stocks
Arthur He's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Vera Therapeutics IncVERA | 3 | Buy | $90.00 | +99.87% | Maintains | a month ago |
Adagene IncADAG | 11 | Buy | $7.00 | +251.76% | Maintains | 4 months ago |
Lava Therapeutics NvLVTX | 11 | Hold | $1.24 | -28.74% | Maintains | 4 months ago |
Aurinia Pharmaceuticals IncAUPH | 1 | Buy | $17.00 | +8.42% | Assumes | 4 months ago |
Nektar TherapeuticsNKTR | 4 | Buy | $120.00 | +109.50% | Maintains | 6 months ago |
Solid Biosciences IncSLDB | 10 | Buy | $20.00 | +250.26% | Reiterates | 6 months ago |
Adaptimmune Therapeutics PLCADAPY | 6 | Buy | $3.00 | +5,455.56% | Maintains | 8 months ago |
Prime Medicine IncPRME | 7 | Buy | $10.00 | +137.53% | Reiterates | 9 months ago |
Poseida Therapeutics IncPSTX | 17 | Hold | $9.00 | N/A | Downgrades | a year ago |
Hookipa Pharma IncHOOK | 6 | Buy | $60.00 | N/A | Maintains | 2 years ago |
Calliditas Therapeutics AbCALT | 4 | Hold | $39.00 | N/A | Downgrades | 2 years ago |
Bioatla IncBCAB | 6 | Buy | $7.00 | N/A | Reiterates | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.